Core Insights - 2025 is a crucial year for Volition as it aims to commercialize its Nu.Q® platform in the human diagnostics market, currently in discussions with over ten companies [1][2] - The company is progressing through various stages of partnership development, including due diligence and contract finalization, with expectations to sign its first agreement in the human diagnostics space this quarter [2][4] - Volition's Nu.Q® technology shows strong clinical evidence for applications in cancer and sepsis, which are areas of increasing interest for pharmaceutical companies [3][4] Business Strategy - The goal for 2025 includes securing multiple licensing agreements in the human diagnostics sector, similar to its successful strategy in the veterinary market, with diverse deal structures anticipated [4] - The company expects potential for upfront and milestone payments, as well as future recurring revenue from these agreements [4] Financial Performance - Volition recorded over $0.4 million in revenue for Q2 2025, marking a 15% growth compared to the same period last year [8] - The net loss decreased by 11% for the quarter and 24% for the first half of 2025 compared to the previous year [8] - Cash used in operating activities for the first half of 2025 was $10.6 million, down 30% year-over-year, with cash and cash equivalents totaling approximately $2.3 million as of June 30, 2025 [8]